Melanotan 1 vs 2: Receptor Selectivity Compared

Both compounds act on a family of five class A GPCRs, all signaling principally through Gs and cAMP, and all responsive to α-MSH-derived ligands:

An analogue's pattern across MC1R and MC3R–MC5R — not its potency at any one of them — is what defines its research utility, because selectivity determines which pathway an observed effect can be attributed to.

Melanotan I ([Nle⁴, D-Phe⁷]-α-MSH, also called afamelanotide) is a linear 13-residue peptide (~1,647 Da) — the same length as native α-MSH, with two targeted substitutions on the natural sequence:

• Nle⁴ (norleucine replacing methionine at position 4) removes an oxidation-prone residue.
• D-Phe⁷ (the D-enantiomer of phenylalanine at position 7) blocks enzymatic degradation and rigidifies the critical His-Phe-Arg-Trp message sequence.

Both substitutions target the same problem — native α-MSH is short-lived and easily degraded — and the resulting analogue was reported as substantially more potent and far more stable than the parent hormone in the classic characterization work (Sawyer TK, et al. Proc Natl Acad Sci USA. 1980;77(10):5754–5758). Its receptor profile is comparatively MC1R-preferring, which is exactly why it remains the reference ligand in melanocyte-model research: an effect observed with Melanotan I in such a system can be attributed to MC1R signaling with reasonable confidence. Full single-compound treatment: Melanotan 1.

Melanotan II is a cyclic 7-residue peptide (~1,024 Da) — structurally a much more radical departure. The chain is truncated to the core message region and then closed into a ring through a lactam bridge between an aspartate and a lysine side chain, locking the message sequence into a fixed β-turn conformation rather than letting it sample freely in solution (Al-Obeidi F, et al. J Med Chem. 1989;32(12):2555–2561).

Conformational constraint is a standard medicinal-chemistry strategy: it raises potency by pre-organizing the ligand into its binding-competent shape, and it improves metabolic stability by denying proteases a flexible extended backbone. In this case it did both — and produced broad, non-selective agonism across MC1R, MC3R, MC4R, and MC5R. That non-selectivity is Melanotan II's defining pharmacological property, and the reason it is used in melanocortin research as a pan-agonist tool rather than a pathway-specific probe (Hadley ME, Dorr RT. Peptides. 2006;27(4):921–930). Full single-compound treatment: Melanotan 2.

Selectivity determines attributability. In a system expressing several melanocortin receptors, an effect seen with a broad agonist cannot be assigned to one subtype without additional controls; the same effect seen with a selective ligand can. Designs frequently use both — the selective analogue to test a specific pathway, the pan-agonist to establish the family-wide ceiling.

Cyclization is the transferable lesson. The comparison is a compact case study in conformational constraint: closing a ring raised potency and stability while broadening receptor engagement. Rigidity and selectivity are not the same axis, and this pair is the standard illustration.

Identity testing distinguishes them trivially. ~1,647 Da linear versus ~1,024 Da cyclic — a 600-Da gap and a different topology. Mass spectrometry separates the two without ambiguity, and cyclization itself carries a mass signature (loss of water at ring closure) relative to the corresponding linear sequence. Certificates of Analysis are published on product pages as testing is completed — review the report before you order. Product specifications: Melanotan 1 · Melanotan 2.